LIONEL VASQUEZ: Open Payments
NPI 1285460303 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,329 in 39 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $64 · 2025 $1,329
Food & beverage: $1,329
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $495 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $311 |
| AstraZeneca Pharmaceuticals LP | 9 | $256 |
| Janssen Pharmaceuticals, Inc | 3 | $159 |
| Novo Nordisk Inc | 3 | $48 |
| Dexcom, Inc. | 1 | $19 |
| Amgen Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
Products named: QULIPTA, CAPLYTA, AIRSUPRA, SPRAVATO, VRAYLAR, BREZTRI, Ozempic, MAVYRET.
Industry payments across AZ — which companies pay providers there.
